MedTrace Logo

Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial

NCT01597557 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 261

Last updated 2020-10-22

Study results available
· View outcomes & findings →

Summary

The proposed study is designed to evaluate the effect of an intravenous infusion of magnesium sulfate in facilitating successful cardioversion of atrial fibrillation and in decreasing the energy threshold (in J) required for successful cardioversion of atrial fibrillation into sinus rhythm.

Conditions

Interventions

DRUG

Magnesium Sulfate

2 grams intravenous drip over 30 minutes

OTHER

Placebo

Normal Saline 50 ml intravenous drip over 30 minutes

Sponsors & Collaborators

  • State University of New York at Buffalo

    lead OTHER

Principal Investigators

  • Anne B Curtis, MD · State University of New York at Buffalo

  • Bharath Rajagopalan, MBBS · State University of New York at Buffalo

  • Anne B Curtis, MD · State University of New York at Buffalo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01597557 on ClinicalTrials.gov